Overview

• A new immunotherapy targets hematopoietic stem cells to rebalance the immune system, making it more youthful in mice.
• The treatment, developed by scientists at Stanford University and NIH, could potentially extend to humans, offering a way to combat age-related immune decline.
• Older mice treated with the antibody showed a significant increase in adaptive immune cells and a decrease in pro-inflammatory markers.
• The therapy's effects were durable, lasting up to 16 weeks, and improved the mice's response to vaccination.
• Experts caution that while promising, further research is needed to understand potential human applications and long-term effects.